These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 24141698)
1. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Schwartzberg L; Barbour SY; Morrow GR; Ballinari G; Thorn MD; Cox D Support Care Cancer; 2014 Feb; 22(2):469-77. PubMed ID: 24141698 [TBL] [Abstract][Full Text] [Related]
2. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415 [TBL] [Abstract][Full Text] [Related]
3. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425 [TBL] [Abstract][Full Text] [Related]
4. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S; Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083 [TBL] [Abstract][Full Text] [Related]
5. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060 [TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Suzuki K; Yamanaka T; Hashimoto H; Shimada Y; Arata K; Matsui R; Goto K; Takiguchi T; Ohyanagi F; Kogure Y; Nogami N; Nakao M; Takeda K; Azuma K; Nagase S; Hayashi T; Fujiwara K; Shimada T; Seki N; Yamamoto N Ann Oncol; 2016 Aug; 27(8):1601-6. PubMed ID: 27358385 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Boccia R; Grunberg S; Franco-Gonzales E; Rubenstein E; Voisin D Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552 [TBL] [Abstract][Full Text] [Related]
8. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Raftopoulos H; Cooper W; O'Boyle E; Gabrail N; Boccia R; Gralla RJ Support Care Cancer; 2015 Mar; 23(3):723-32. PubMed ID: 25179689 [TBL] [Abstract][Full Text] [Related]
9. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844 [TBL] [Abstract][Full Text] [Related]
10. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119 [TBL] [Abstract][Full Text] [Related]
11. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Rubenstein EB Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194 [TBL] [Abstract][Full Text] [Related]
12. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy. Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006 [TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358 [TBL] [Abstract][Full Text] [Related]
14. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643 [TBL] [Abstract][Full Text] [Related]
15. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Aapro MS; Grunberg SM; Manikhas GM; Olivares G; Suarez T; Tjulandin SA; Bertoli LF; Yunus F; Morrica B; Lordick F; Macciocchi A Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447 [TBL] [Abstract][Full Text] [Related]
17. Palonosetron: in the prevention of nausea and vomiting. Yang LP; Scott LJ Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528 [TBL] [Abstract][Full Text] [Related]
18. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy. Boccia R; O'Boyle E; Cooper W BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC). Hesketh PJ; Morrow G; Komorowski AW; Ahmed R; Cox D Support Care Cancer; 2012 Oct; 20(10):2633-7. PubMed ID: 22733373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]